United BioSource Corporation

United BioSource Corporation is a US-based firm focused on enhancing access to specialty therapies through comprehensive patient services, safety measures, and evidence generation strategies. United BioSource Corporation, founded in 2003 and headquartered in King of Prussia, US, specializes in connecting patients to specialty therapies. The firm was acquired by Avista Capital Partners in December 2017 from Express Scripts Holding Company, which has enabled its service expansion. Dennis Mohamed is the Founder, and Bekki Brown, Milan Hodas, and Ruby B are part of the executive leadership team.

UBC specializes in connecting specialty therapies with patients who need them by providing comprehensive services in access, safety, and evidence generation. The company offers a range of solutions tailored to the unique needs of healthcare providers, patients, and stakeholders in the biopharma sector. Their core offerings include risk management, evidence development, and patient access solutions, which are designed to mitigate barriers in therapy delivery and enhance patient outcomes. UBC employs seasoned professionals to generate real-world evidence strategies that align with various stakeholders, including patients, providers, regulators, and payers.

Their services are utilized in diverse geographical markets, focusing on therapeutic areas such as oncology, rare diseases, cell therapy, and gene therapy, primarily in North America and Europe. UBC's revenue is primarily generated through long-term partnerships and collaborations with biopharmaceutical companies, healthcare providers, and payers. The firm adopts a B2B transaction structure, providing tailored solutions through contracts that may include service agreements for evidence generation and patient access support. Clients may engage UBC for specific programs or ongoing support, which is often structured around project milestones or subscription models.

Their flagship offerings, such as pharmacovigilance and customized patient safety solutions, form critical parts of the revenue stream. The financial transactions are structured to ensure compliance with regulatory requirements while providing value-driven outcomes, supporting both therapeutic development and patient adherence initiatives. The acquisition of United BioSource Corporation by Avista Capital Partners in December 2017 aims to facilitate growth and expand the firm's service offerings. Although specific new products have not been disclosed, the company is expected to enhance its impact in the specialty therapy sector.

The firm is also focused on expanding its reach into additional geographical markets, particularly within North America and Europe, to better serve healthcare providers and patients. The resources and strategic direction provided by the recent acquisition are intended to support these growth initiatives.